Alpha-Beta Technology Inc. has completed a $3 million privatefinancing from Concord Partners and Advent International fund continued development of its carbohydrate-basedproducts. The Worcester, Mass., company said it hopes to beginPhase I clinical trials this year of its Betafectin anti-infective. Alpha-Beta has three drugs in preclinical studies:Cholestran, a cholesterol-lowering therapeutic; Fibercel, a fatsubstitute; and Adjuvax, a vaccine adjuvant. The company hasraised $3.5 million in previous financing rounds since it wasfounded in March 1988.

(c) 1997 American Health Consultants. All rights reserved.